Benitec Biopharma Inc.
BNTC Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$8.59
KIRA · Stoqly’s AI analyst, in plain words
- Benitec Biopharma Inc. lost $45.5M in fiscal 2026.
- Free cash flow was −$16.6M in fiscal 2026, — of revenue.
Market cap
$400M
P/E
—
Revenue
—
Net income
−$45.5M
Free cash flow
−$16.6M
Operating margin
—
Benitec Biopharma Inc. in 30 seconds · fiscal 2026
Does it make a profit?
−$45.5M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Benitec Biopharma Inc. does
No business description yet.
- Fiscal year ends
- June 30, 2026
- Latest annual report
- 10-K · Sep 14, 2026
- Legal name
- Benitec Biopharma Inc.
- CIK
- 0001808898
Benitec Biopharma Inc. · BNTC
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.1M | $0.1M | $0.0M | — | — |
| Revenue growth | 23.7% | 2.7% | −100.0% | — | — |
| Operating margin | −24,457.5% | −25,441.3% | — | — | — |
| Net income | −$18.2M | −$19.6M | −$21.8M | −$37.9M | −$45.5M |
| Net margin | −24,942.5% | −26,082.7% | — | — | — |
| Diluted EPS | −$37.88 | −$14.12 | −$1.22 | −$1.05 | −$0.98 |
| Cash | |||||
| Cash from operations | −$15.9M | −$18.0M | −$19.4M | −$23.6M | −$16.5M |
| Capital expenditure | $0.0M | $0.0M | $0.2M | $0.0M | $0.1M |
| Free cash flow | −$15.9M | −$18.0M | −$19.6M | −$23.6M | −$16.6M |
| FCF margin | −21,797.3% | −24,017.3% | — | — | — |
| Share count change | −88.8% | 188.3% | 1,225.2% | 97.2% | 28.6% |
| Debt and strength | |||||
| Cash and short-term investments | $4.1M | $2.5M | $50.9M | $97.7M | $180M |
| Shareholders' equity | $2.9M | $0.2M | $47.2M | $97.3M | $177M |
| Current ratio | 1.9x | 0.9x | 10.5x | 54.7x | 34.0x |
| Returns and quality | |||||
| Return on equity | −159.1% | −1,268.6% | −91.7% | −52.5% | −33.2% |
| Return on tangible equity | −631.8% | −9,684.2% | −47.3% | −39.0% | −25.7% |
| Piotroski F-score | 3 | 2 | 3 | — | — |
| Altman Z'' | −97.6 | −151.6 | 1.1 | 40.6 | 32.7 |
Insiders bought, 12 months
$22.4M
3 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Benitec Biopharma Inc. · BNTC
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $8.59 a share, the company is worth $400M.
Source: SEC EDGAR XBRL filings (CIK 0001808898). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.